ONCOC4 ANNOUNCES FIRST PATIENT DOSED IN PRESERVE-004, A PHASE 2 CLINICAL TRIAL OF ONC-392 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma
Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp